MedTrace Logo

Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer

NCT00004087 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-06-22

No results posted yet for this study

Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by monoclonal antibody therapy used to kill tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody plus peripheral stem cell transplantation in treating patients who have metastatic or recurrent colorectal cancer or pancreatic cancer that has not responded to previous treatment.

Conditions

Interventions

BIOLOGICAL

filgrastim

as prescribed by physician

PROCEDURE

autologous bone marrow transplantation

1-2 weeks before treatment

PROCEDURE

peripheral blood stem cell transplantation

1-2 weeks before treatment

RADIATION

indium In 111 monoclonal antibody MN-14

intravenous infusion over 30 min; single dose

RADIATION

yttrium Y 90 monoclonal antibody MN-14

intravenous infusion over 30 min; single dose

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Garden State Cancer Center at the Center for Molecular Medicine and Immunology

    lead OTHER

Principal Investigators

  • Jack D. Burton, MD · Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-03-31
Primary Completion
2001-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004087 on ClinicalTrials.gov